Catelyn Coyle1,2, Anne C Moorman3, Tyler Bartholomew2, Gary Klein4, Helena Kwakwa5, Shruti H Mehta1, Deborah Holtzman3. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 2. National Nurse-Led Care Consortium, Philadelphia, PA. 3. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA. 4. Public Health Management Corporation, Philadelphia, PA. 5. Philadelphia Department of Public Health, Philadelphia, PA.
Abstract
Improving care and treatment for persons infected with hepatitis C virus (HCV) can reduce HCV-related morbidity and mortality. Our primary objective was to examine the HCV care continuum among patients receiving care at five federally qualified health centers (FQHCs) in Philadelphia, PA, where a testing and linkage to care program had been established. Among the five FQHCs, one served a homeless population, two served public housing residents, one served a majority Hispanic population, and the last, a "test and treat" site, also provided HCV treatment to patients. We analyzed data from electronic health records of patients tested for HCV antibody from 2012 to 2016 and calculated the percentage of patients across nine steps of the HCV care continuum ranging from diagnosis to cure. We further explored factors associated with successful patient navigation through two steps of the continuum using multivariable logistic regression. Of 885 chronically infected patients, 92.2% received their RNA-positive result, 82.7% were referred to an HCV provider, 69.4% were medically evaluated by the provider, 55.3% underwent liver disease staging, 15.0% initiated treatment, 12.0% completed treatment, 8.7% were assessed for sustained virologic response (SVR), and 8.0% achieved SVR. Regression results revealed that test and treat site patients were significantly more likely to be medically evaluated (adjusted odds ratio [aOR], 2.76; 95% confidence interval [CI], 1.82-4.17) and to undergo liver disease staging (aOR, 1.92; 95% CI, 1.02-2.86) than patients at the other FQHCs combined. Conclusion: In this US urban setting, over two thirds of HCV-infected patients were linked to care; although treatment uptake was low overall, it was highest at the test and treat site; scaling up treatment services in HCV testing settings will be vital to improve the HCV care continuum.
Improving care and treatment for personsinfected with hepatitis C virus (HCV) can reduce HCV-related morbidity and mortality. Our primary objective was to examine the HCV care continuum among patients receiving care at five federally qualified health centers (FQHCs) in Philadelphia, PA, where a testing and linkage to care program had been established. Among the five FQHCs, one served a homeless population, two served public housing residents, one served a majority Hispanic population, and the last, a "test and treat" site, also provided HCV treatment to patients. We analyzed data from electronic health records of patients tested for HCV antibody from 2012 to 2016 and calculated the percentage of patients across nine steps of the HCV care continuum ranging from diagnosis to cure. We further explored factors associated with successful patient navigation through two steps of the continuum using multivariable logistic regression. Of 885 chronically infectedpatients, 92.2% received their RNA-positive result, 82.7% were referred to an HCV provider, 69.4% were medically evaluated by the provider, 55.3% underwent liver disease staging, 15.0% initiated treatment, 12.0% completed treatment, 8.7% were assessed for sustained virologic response (SVR), and 8.0% achieved SVR. Regression results revealed that test and treat site patients were significantly more likely to be medically evaluated (adjusted odds ratio [aOR], 2.76; 95% confidence interval [CI], 1.82-4.17) and to undergo liver disease staging (aOR, 1.92; 95% CI, 1.02-2.86) than patients at the other FQHCs combined. Conclusion: In this US urban setting, over two thirds of HCV-infectedpatients were linked to care; although treatment uptake was low overall, it was highest at the test and treat site; scaling up treatment services in HCV testing settings will be vital to improve the HCV care continuum.
Authors: Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward Journal: MMWR Recomm Rep Date: 2012-08-17
Authors: Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg Journal: Ann Intern Med Date: 2014-03-04 Impact factor: 25.391
Authors: David R Nelson; James N Cooper; Jacob P Lalezari; Eric Lawitz; Paul J Pockros; Norman Gitlin; Bradley F Freilich; Ziad H Younes; William Harlan; Reem Ghalib; Godson Oguchi; Paul J Thuluvath; Grisell Ortiz-Lasanta; Mordechai Rabinovitz; David Bernstein; Michael Bennett; Trevor Hawkins; Natarajan Ravendhran; Aasim M Sheikh; Peter Varunok; Kris V Kowdley; Delphine Hennicken; Fiona McPhee; Khurram Rana; Eric A Hughes Journal: Hepatology Date: 2015-03-10 Impact factor: 17.425
Authors: Stephanie A S Staras; Yi Guo; Valeria V Gordan; Gregg H Gilbert; Deborah L McEdward; Douglas Manning; Jennifer Woodard; Elizabeth A Shenkman Journal: J Am Dent Assoc Date: 2020-12-01 Impact factor: 3.634
Authors: Maria A Corcorran; Judith I Tsui; John D Scott; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: A Seaman; C A King; T Kaser; A Geduldig; W Ronan; R Cook; B Chan; X A Levander; K C Priest; P T Korthuis Journal: Int J Drug Policy Date: 2021-07-27
Authors: Risha Irvin; Boatemaa Ntiri-Reid; Mary Kleinman; Tracy Agee; Jeffrey Hitt; Onyeka Anaedozie; Tolu Arowolo; Hope Cassidy-Stewart; CaSaundra Bush; Lucy E Wilson; Alexander J Millman; Noele P Nelson; Lauren Canary; Sherilyn Brinkley; Juhi Moon; Oluwaseun Falade-Nwulia; Mark S Sulkowski; David L Thomas; Michael T Melia Journal: J Viral Hepat Date: 2020-08-05 Impact factor: 3.517